Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.

ABSTRACT: Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer and the third leading cause of cancer mortality worldwide. The development of effective systemic therapies, particularly those involving immune-checkpoint inhibitors (ICIs), has substantially improved the outcomes of patients with advanced-stage HCC. Approximately 30% of patients are diagnosed with early stage disease and currently receive potentially curative therapies, such as resection, liver transplantation or local ablation, which result in median overall survival durations beyond 60 months. Nonetheless, up to 70% of these patients will have disease recurrence within 5 years of resection or local ablation. To date, the results of randomized clinical trials testing adjuvant therapy in patients wi

SUBMITTER: Llovet JM 

PROVIDER: S-EPMC11984461 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature